ESR1 and neoplasm: According to the clinicopathological characteristics showed in Table 1, patients with low RECQL mRNA expression tend to be lymph node-positive (34.5% vs. 27.0%, P = 0.026), tumor grade III (19.8% vs.13.2%, P = 0.041), HER2-positive (34.0% vs. 21.8%, P < 0.001), ER-negative (32.1% vs. 25.6%,P = 0.047), and Luminal B (HER2+) subtype (P = 0.003) (Table 1).